An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
Launched by KYOWA KIRIN CO., LTD. · Apr 3, 2012
Trial Information
Current as of June 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Satisfactory completion of KKP's sponsored KRN23-INT-001 clinical trial
- • 2. eGFR ≥ 60 mL/min
- • 3. Corrected Ca \< 10.8 mg/dL
- • 4. For female of child-bearing potential, a negative serum pregnancy test
- • 5. A willingness to utilize adequate contraception and not become pregnant \[or to have their partner(s) become pregnant\] during the study
- • 6. Additional inclusion criteria apply
- Exclusion Criteria:
- • 1. Subject experienced a safety-related event in the KRN23-INT-001 study
- • 2. Pregnant or lactating female subject or pregnant or female planning to become pregnant during the study
- • 3. Receipt of a live (attenuated) vaccine (except for influenza vaccines) during the course of the KRN23-INT-001 study and/or of this study
- • 4. Condition which could present a concern for either the subject's safety or difficulty with data interpretation
- • 5. Additional exclusion criteria apply
About Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. is a global pharmaceutical company headquartered in Japan, dedicated to the discovery, development, and commercialization of innovative therapies to address unmet medical needs. With a strong emphasis on biotechnology, the company focuses on areas such as oncology, nephrology, and immunology, leveraging advanced research and development capabilities to enhance patient outcomes. Kyowa Kirin is committed to ethical practices and collaboration in clinical trials, ensuring the highest standards of safety and efficacy in its therapeutic offerings. Through its dedication to scientific excellence and patient-centric approaches, Kyowa Kirin strives to improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
San Francisco, California, United States
New Haven, Connecticut, United States
Durham, North Carolina, United States
Montreal, Quebec, Canada
Indianapolis, Indiana, United States
Patients applied
Trial Officials
Amy Zhang, PhD
Study Director
Kyowa Hakko Kirin Pharma, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials